Original articleIntravitreal Triamcinolone Acetonide for Diffuse Diabetic Macular Edema: Phase 2 Trial Comparing 4 mg vs 2 mg
Section snippets
Methods
This study was an interventional case series. The protocol was approved by the Institutional Review Board of the Hôpital Saint-Louis (Paris, France).
Patients were included if biomicroscopy revealed diffuse DME, if they were unresponsive to laser photocoagulation despite previous maximal focal and grid laser, and if they had no signs of vitreomacular traction or epiretinal membrane on either biomicroscopy or OCT examination. On biomicroscopy, diffuse macular edema was defined by macular
Results
Between January 2002 and September 2004, 35 patients fulfilled the inclusion criteria and agreed to participate in the study. Three were excluded because of an IOP increase exceeding 15 mm Hg after one month of treatment with topical dexamethasone 0.1%.
Thirty-two patients (32 eyes) were therefore included, and all except two completed the scheduled follow-up: one patient in the 4 mg group developed central venous occlusion that required laser photocoagulation after the 12-week follow-up visit,
Discussion
Intravitreal injection of 4 mg TA has been reported to have a dramatic effect on DME.2, 3, 4, 5, 6, 7 The aim of the present study was to find out whether a lower dose of 2 mg TA could be as effective as 4 mg and have fewer side effects.
We observed a dramatic decrease in CMT after intravitreal injection of both doses, with mean decreases in thickening of 73% and 69% at three months in the 4- and 2-mg groups, respectively. The between-group difference in the change in thickening was not
François Audren, MD, obtained his degree at the Rennes Medical School (France) in 1998 and his MD degree in Paris, France in 2003. He graduated in 2002 with a master of Experimental and Clinical Pharmacology. Since 2004, Dr Audren has held a fellowship Doctor Caputo’s in the Department of Pediatric Ophthalmology at the Rosthchild Foundation in Paris. Dr Audren’s research interests are in triamcinolone treatment of diabetic macular edema; his clinical interests are in the area of pediatric
References (17)
- et al.
Visual impairment in diabetes
Ophthalmology
(1984) - et al.
Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema
Am J Ophthalmol
(2004) - et al.
Inter-eye difference in diabetic macular edema after unilateral intravitreal injection of triamcinolone acetonide
Am J Ophthalmol
(2004) - et al.
Intravitreal triamcinolone for refractory diabetic macular edema
Ophthalmology
(2002) - et al.
Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial
Ophthalmology
(2004) - et al.
Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial
Ophthalmology
(2004) - et al.
Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection
Ophthalmology
(2003) - et al.
Intraocular pressure elevation after intravitreal triamcinolone acetonide injection
Ophthalmology
(2005)
Cited by (71)
Ocular hypertension following 40 mg sub-Tenon triamcinolone versus 0.7 mg dexamethasone implant versus 2 mg intravitreal triamcinolone
2020, Canadian Journal of OphthalmologyCurrent Treatments for Diabetic Macular Edema
2023, International Journal of Molecular SciencesDiabetic retinopathy impact on intraocular pressure during corticosteroid therapy
2022, Fyodorov Journal of Ophthalmic SurgerySuprachoroidal versus Intravitreal Triamcinolone Acetonide for the Treatment of Diabetic Macular Edema
2022, Clinical Ophthalmology
François Audren, MD, obtained his degree at the Rennes Medical School (France) in 1998 and his MD degree in Paris, France in 2003. He graduated in 2002 with a master of Experimental and Clinical Pharmacology. Since 2004, Dr Audren has held a fellowship Doctor Caputo’s in the Department of Pediatric Ophthalmology at the Rosthchild Foundation in Paris. Dr Audren’s research interests are in triamcinolone treatment of diabetic macular edema; his clinical interests are in the area of pediatric ophthalmology, strabismus, and neuroophthalmology.
Pascale Massin, MD, PhD, went to Pitié-Salpétrière, Paris University 6 where she obtained her Medical Degree, Paris, France. Dr Massin did her Resident in Ophthalmology, Assistance Publique at Paris University, Paris France and her fellowship at the Ophthalmology department of the Hôpital Lariboisière, Paris University 7, Paris, France. Dr Massin’s interest includes medical and surgical retina, especially macular surgery and diabetic retinopathy. Evaluation and treatment of diabetic macular edema; macular dystrophies associated to mitochondrial diabetes, screening for diabetic retinopathy using telemedicine.